News Releases

CUPERTINO, Calif. , Nov. 13, 2020 /PRNewswire/ -- DURECT Corporation  (Nasdaq: DRRX) today presented additional safety data and efficacy signals from its Phase 1b clinical trial of DUR-928 in nonalcoholic steatohepatitis (NASH) patients in a poster presentation at The AASLD Liver Meeting Digital

CUPERTINO, Calif. , Nov. 10, 2020 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced that Norman Sussman , MD, FAASLD, newly appointed Chief Medical Officer, will host a webinar on the treatment landscape and unmet medical need in treating patients with alcoholic hepatitis (AH), as

Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET CUPERTINO, Calif. , Nov. 2, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2020 and provided a corporate update.

CUPERTINO, Calif. , Nov. 2, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on the development of treatments for acute organ injury and chronic liver diseases, today announced it has appointed Norman Sussman , M.D.

CUPERTINO, Calif. , Oct. 27, 2020 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced that it will report third quarter 2020 financial results and host a conference call after the market close on Monday, November 2, 2020. Monday, November 2 @ 4:30pm Eastern Time   / 1:30 p.m.

CUPERTINO, Calif. , Oct. 26, 2020 /PRNewswire/ -- DURECT Corporation  (Nasdaq: DRRX) today announced that it will partipate in the ROTH Capital Healthcare Event, " Covid-19 Therapeutics in Development ," taking place on Wednesday, October 28, 2020 .  The ROTH Healthcare and Biotechnology team are

CUERTINO, Calif., Oct. 5, 2020 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced it will present a poster at The AASLD Liver Meeting Digital Experience ™ (TLMdX) 2020 , to be held virtually on November 13-16, 2020 .  Topline results from the 4-week Phase 1b clinical study of orally

CUPERTINO, Calif. , Sept. 30, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President, CEO, Michael H. Arenberg , Chief Financial Officer, and Dr. WeiQi Lin , Executive Vice President of R&D will be participating in a fireside chat hosted by Ed Arce of

CUPERTINO, Calif. , Sept. 23, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 patients with

Phase 2b study in subjects with Alcoholic Hepatitis to evaluate safety and efFIcacy of DUR-928 treatMent (AHFIRM) CUPERTINO, Calif. , Sept. 22, 2020 /PRNewswire/ --  DURECT Corporation (NASDAQ: DRRX) today announced the study design for the Phase 2b AHFIRM clinical trial of DUR-928 in severe

CUPERTINO, Calif. , Sept. 10, 2020 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that it will participate in the HC Wainwright 22nd Annual Global Investment Conference , Cantor Fitzgerald Virtual Global Healthcare Conference and Oppenheimer Fall Healthcare Life Sciences &

CUPERTINO, Calif. , Aug. 27, 2020 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced the presentation of pharmacokinetic (PK) data from a Phase 2a study of DUR-928 in alcoholic hepatitis (AH) at the Digital International Liver Congress™ 2020 (EASL) , taking place on August 27-29 .

CUPERTINO, Calif. , Aug. 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President, CEO, Michael H. Arenberg , Chief Financial Officer and Dr. WeiQi Lin , Executive Vice President of R&D will be participating in a fireside chat hosted by Ellie Merle

CUPERTINO, Calif. , Aug. 5, 2020 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, Michael H. Arenberg , Chief Financial Officer and Dr. WeiQi Lin , Executive Vice President of R&D will be participating in a fireside chat at the BTIG

Live Webcast of Earnings Call Today, August 3rd at 4:30 p.m. ET CUPERTINO, Calif. , Aug. 3, 2020 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2020 and provided a corporate update.

CUPERTINO, Calif. , July 28, 2020 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced that it will report second quarter 2020 financial results and host a conference call after the market close on Monday, August 3, 2020. Monday, August 3 @ 4:30pm Eastern Time   / 1:30 p.m.

- U.S. Food and Drug Administration (FDA) has authorized the investigational new drug (IND) application   - Acute liver and kidney injury are risk factors for poor outcomes in COVID-19 patients   - The risk of death from multi-organ failure is present in both patients with severe COVID-19 and those

CUPERTINO, Calif. , June 29, 2020 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced that it is set to join the broad-market Russell 3000 ® Index as a result of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens today, June 29, 2020 .

CUPERTINO, Calif. , June 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Gilead Sciences, Inc., (Gilead) has provided notice that, effective as of December 22, 2020 , it is terminating the License Agreement dated July 19, 2019 and a related R&D agreement between

CUPERTINO, Calif. , May 28, 2020 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, will be presenting at the Jefferies 2020 Virtual Health Care Conference , Wednesday, June 3, 2020 at 10:00 a.m. EDT / 7:00 a.m.

-- Improvements in both serum liver enzymes and liver imaging -- Improvement in serum lipid profile -- DUR-928 was well tolerated with no significant adverse events -- Promising data support further development of DUR-928 in NASH CUPERTINO, Calif. , May 26, 2020 /PRNewswire/ -- DURECT Corporation

Working on Proof-of-Concept Phase 2 Trial in COVID-19 Patients with Acute Liver or Kidney Injury Live Webcast of Earnings Call Today, May 11th at 4:30 p.m. ET CUPERTINO, Calif. , May 11, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months

CUPERTINO, Calif. , May 4, 2020   DURECT Corporation  (Nasdaq: DRRX) today announced that it will report first quarter 2020 financial results and host a conference call after the market close on Monday, May 11, 2020. Monday May 11 th   @ 4:30pm Eastern Time / 1:30 p.m.

Fourth Quarter Highlighted by Presentation of Positive DUR-928 Phase 2a Alcoholic Hepatitis Data at the Liver Meeting® 2019 Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , March 3, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial

CUPERTINO, Calif. , Feb. 26, 2020 /PRNewswire / -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and year ended December 31, 2019 financial results and host a conference call after the market close on Tuesday, March 3, 2020 .

CUPERTINO, Calif. , Jan. 17, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration's ( FDA ) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) met yesterday to discuss the Class 2 New Drug Application (NDA) resubmission

CUPERTINO, Calif. , Jan. 16, 2020 /PRNewswire/ -- DURECT Corporation  (Nasdaq: DRRX) today announced that NASDAQ has halted trading of the Company's common stock today. The U.S. Food and Drug Administration's ( FDA ) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is holding a

CUPERTINO, Calif. , Jan. 2, 2020 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two patients completed the study, applying DUR-928 topically to the plaque on one

CUPERTINO, Calif. , Nov. 15, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, will be presenting at the Stifel 2019 Health Care Conference , at the Lotte New York Palace Hotel on Tuesday, November 19, 2019 at 3:35 p.m.

Live Webcast of Data Presentation and Discussion by KOL, Tarek I. Hassanein, M.D. at Noon ET on Tuesday, November 12, 2019 CUPERTINO, Calif. , Nov. 12, 2019 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in alcoholic

Call will feature data from DURECT's late-breaking oral presentation at the 2019 Liver Meeting® CUPERTINO, Calif. , Nov. 6, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that it will host a key opinion leader (KOL) conference call and live webcast to discuss the results of

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Nov. 4, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2019 and provided a corporate update.

CUPERTINO, Calif. , Oct. 30, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that it will report third quarter and nine months ended September 30, 2019 financial results and host a conference call after the market close on Monday, November 4, 2019 .

Study Results Were Selected for Inclusion in the "Best of The Liver Meeting" Summary Slide Presentation Poster Comparing DUR-928 Data to Historical Control Will Also be Presented CUPERTINO, Calif. , Oct. 21, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that the results

CUPERTINO, Calif. , Oct. 17, 2019 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) announced today that it will be presenting at two upcoming investor conferences focused on non-alcoholic steatohepatitis (NASH): the H.C. Wainwright 3 rd Annual NASH Investor Conference , to be held in New York

  CUPERTINO, Calif. , Oct. 7, 2019 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced that it has completed enrollment in its Phase 2a clinical trial of topical DUR-928 in patients with mild to moderate plaque psoriasis. The company also announced that it has now enrolled 30 of the

  CUPERTINO, Calif. , Oct. 2, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that the U.S. Food and Drug Administration ( FDA ) has notified the Company that its Class 2 NDA resubmission for POSIMIR ® (bupivacaine extended-release solution) will be discussed at a meeting of

  CUPERTINO, Calif. , Sept. 26, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , Chief Executive Officer will be presenting at the Cantor Fitzgerald Global Health Care Conference , at the InterContinental New York Barclay Hotel on Friday, October 4, 2019

CUPERTINO, Calif. , Sept. 17, 2019 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced that it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, in patients with alcoholic hepatitis (AH). The final enrollment for the trial consists of 12 severe

CUPERTINO, Calif. , Sept. 9, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that further development of a long-acting injectable HIV investigational product utilizing DURECT's SABER ® technology has triggered a $10 million milestone payment from Gilead Sciences, Inc.

CUPERTINO, Calif. , Sept. 4, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference , sponsored by H. C.

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Aug. 1, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2019 and provided a corporate update.

CUPERTINO, Calif. , July 25, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that it will report second quarter and six months ended June 30, 2019 financial results and host a conference call after the market close on Thursday, August 1, 2019 .

Gilead Also Receives Exclusive Option to License Additional Products for HIV and Hepatitis B CUPERTINO, Calif. , July 22, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Gilead Sciences, Inc.

User Fee Goal Date is December 27, 2019 CUPERTINO, Calif. , July 17, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration ( FDA ) has acknowledged that the submission of DURECT's full response to the Complete Response Letter (CRL) it

CUPERTINO, Calif. , June 27, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has submitted a full response to the Complete Response Letter (CRL) it previously received from U.S. Food and Drug Administration ( FDA ) related to POSIMIR ® (bupivacaine extended-release

CUPERTINO, Calif. , June 25, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it received approval from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") to transfer the listing of the Company's common stock from the Nasdaq Global Market to the

CUPERTINO, Calif. , June 20, 2019 /PRNewswire/ --  DURECT Corporation (" DURECT " or the "Company") (Nasdaq: DRRX) today announced that it has entered into a securities purchase agreement with certain investors pursuant to which, subject to the terms and conditions expressed therein, the Company

CUPERTINO, Calif. , June 18, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed dosing the 90 mg cohort of severe AH patients in its ongoing DUR-928 Phase 2a clinical trial, and that after reviewing safety and pharmacokinetic (PK) data from the completed

CUPERTINO, Calif. , May 16, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , Chief Executive Officer, and Michael H. Arenberg , Chief Financial Officer, will be participating in the 20 th Annual B. Riley FBR Institutional Investor Conference , taking

Live  Webcast of AH Data Presentation and Discussions by KOLs Steven Flamm, M.D., Tarek  I. Hassanein, M.D. and Paul Kwo, M.D. Tomorrow, Wednesday, May 8, 2019 at 8:30  a.m. ET CUPERTINO, Calif., May 7, 2019 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced preliminary data from

Live Webcast of Alcoholic Hepatitis KOL and Earnings Call on Wednesday, May 8th at 8:30 a.m. ET Call will feature discussions by KOLs Steven Flamm, M.D.. Tarek I. Hassanein, M.D., and Paul Kwo, M.D. CUPERTINO, Calif. , May 7, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced

Call will feature discussions by KOLs Steven Flamm, M.D.. Tarek I. Hassanein, M.D., and Paul Kwo, M.D. Conference call and live webcast with slides on Wednesday, May 8th at 8:30 a.m. ET CUPERTINO, Calif. , May 3, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will

CUPERTINO, Calif. , April 25, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today the appointment of two new members to its board of directors.  Dr. Gail M. Farfel , Executive Vice President and Chief Development Officer of Zogenix, Inc. , and Judith J.

CUPERTINO, Calif. , April 1, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Michael Arenberg , Chief Financial Officer, will be presenting at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9 at 10:50 a.m. BST / 05.50 a.m.

CUPERTINO, Calif. , March 27, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient enrollment in a Phase 1b trial with oral DUR-928 in patients with NASH.  DUR-928, the lead investigational product in the Company's Epigenetic Regulator Program, is an

CUPERTINO, Calif. , March 21, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a proof-of-concept trial with topical DUR-928 in patients with mild to moderate plaque psoriasis.  DUR-928, the lead investigational product in the

Advancing To Next Dosing Cohort in Severe Alcoholic Hepatitis (AH) Patients Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , March 7, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended

CUPERTINO, Calif. , March 4, 2019 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Thursday, March 7, 2019 at 4:30 pm Eastern

Live Webcast Today at 10:30 a.m. Eastern Time CUPERTINO, Calif. , Feb. 27, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced it has completed a comprehensive review of its POSIMIR ® (bupivacaine extended-release solution) program and plans to submit a full response to the

CUPERTINO, Calif. , Feb. 21, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown , President and CEO, and Mike Arenberg , Chief Financial Officer, will be participating in the Berenberg NASH Day, taking place Tuesday, February 26, 2019 , at Berenberg's New

Live Webcast Today at 8:00 a.m. Eastern Time CUPERTINO, Calif. , Jan. 7, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) has refined and focused its clinical development strategy for DUR-928, the lead product candidate in its Epigenetic Regulator Program, to prioritize indications with

CUPERTINO, Calif. , Jan. 3, 2019 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) invites interested parties to listen to a corporate update conference call that will be broadcast live over the internet on Monday, January 7, 2019 at 8:00 am Eastern Time ( 5:00 am Pacific Time ).

Indivior PLC Announces Plan for Commercial Launch in February 2019 with 50 Sales Representatives CUPERTINO, Calif. , Dec. 19, 2018 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) stated on December 18, 2018 that it is moving ahead with the launch of

David Hoffmann, Current Lead Independent Director and Chairman of the Audit Committee, to Assume Position of Chairman of the Board CUPERTINO, Calif. , Dec. 17, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Felix Theeuwes will retire as Chairman of the Board and

CUPERTINO, Calif. , Nov. 19, 2018 /PRNewswire/ -- DURECT Corporation  (Nasdaq: DRRX) today announced it has amended its ongoing Phase 2a clinical trial of intravenously administered DUR-928 in patients with alcoholic hepatitis (AH) to accelerate the initiation of dosing of severe AH patents.  The

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Nov. 7, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2018 and provided a corporate update.

CUPERTINO, Calif. , Nov. 1, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, November 7, 2018 at 4:30 pm Eastern

ASN Kidney Week Meeting and American College of Toxicology's Annual Meeting CUPERTINO, Calif. , Oct. 25, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that two posters on DUR-928 will be presented at the ASN Kidney Week Meeting on Saturday, October 27 and one poster will

CUPERTINO, Calif. , Oct. 1, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Michael H. Arenberg to the position of Chief Financial Officer, effective October 15, 2018 . Mr. Arenberg will be responsible for overseeing all financial and capital market

CUPERTINO, Calif. , Sept. 25, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, will be presenting at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 3 at 1:40 p.m.

- ORADUR®-Methylphenidate ER now called Methydur Sustained Release Capsules in Taiwan - Developed by Orient Pharma under a license to the ORADUR® technology from DURECT CUPERTINO, Calif. , Sept. 18, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that Orient Pharma Co., Ltd.

Milestone payment triggered by NDA approval of PERSERIS™ (risperidone) CUPERTINO, Calif. , Aug. 30, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has received a $5 million milestone payment from Indivior PLC (LON: INDV), triggered by Indivior's approval of the New

CUPERTINO, Calif. , Aug. 27, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, will be presenting at the 20 th Annual Rodman & Renshaw Global Investment Conference , sponsored by H.C. Wainwright & Co.

CUPERTINO, Calif. , Aug. 6, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) reported that it received a Complete Response Letter from the U.S. Food and Drug Administration ( FDA ) for Pain Therapeutics' New Drug Application

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Aug. 1, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2018 and provided a corporate update.

Approval triggers $5 million milestone payment to DURECT and future earn-out payments based on U.S. net sales CUPERTINO, Calif. , July 30, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) has reported that the U.S.

CUPERTINO, Calif. , July 24, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, August 1, 2018 at 4:30 pm Eastern

CUPERTINO, Calif. , June 26, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today reported that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S.

CUPERTINO, Calif. , May 9, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced it has entered into an amendment (the "Amendment") to the development and commercialization agreement with Sandoz AG , a division of Novartis (NYSE: NVS), regarding POSIMIR ® (SABER ® -bupivacaine) in

CUPERTINO, Calif. , May 9, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced it has entered into an amendment (the "Amendment") to the development and commercialization agreement with Sandoz AG , a division of Novartis (NYSE: NVS), regarding POSIMIR ® (SABER ® -bupivacaine) in

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , May 2, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2018 and provided a corporate update.

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , May 2, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2018 and provided a corporate update.

CUPERTINO, Calif. , April 25, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with alcoholic hepatitis (AH).  DUR-928, the lead investigational product in our Epigenetic Regulator Program, is

CUPERTINO, Calif. , April 25, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with alcoholic hepatitis (AH).  DUR-928, the lead investigational product in our Epigenetic Regulator Program, is

CUPERTINO, Calif. , April 24, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, May 2, 2018 at 4:30 pm Eastern

CUPERTINO, Calif. , April 24, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, May 2, 2018 at 4:30 pm Eastern

CUPERTINO, Calif. , March 29, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of alcoholic hepatitis (AH) on Thursday, April 5 at 11:00 a.m. Eastern Time . The call will feature a presentation by KOL Paul Kwo, MD,

CUPERTINO, Calif. , March 20, 2018 /PRNewswire/ --   DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that the U.S. Food and Drug Administration ( FDA ) will hold an Advisory Committee Meeting to discuss the New Drug

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , March 1, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2017 and provided a corporate update.

CUPERTINO, Calif. , Feb. 26, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with primary sclerosing cholangitis (PSC).  DUR-928, the lead investigational product in our Epigenetic Regulator

CUPERTINO, Calif. , Feb. 22, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Thursday, March 1, 2018 at 4:30 pm Eastern

CUPERTINO, Calif. , Feb. 20, 2018 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of primary sclerosing cholangitis (PSC) on Monday, February 26 at 12:00 p.m. Eastern Time .

CUPERTINO, Calif. , Feb. 14, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that it has resubmitted the New Drug Application (NDA) for REMOXY ® ER to the U.S.

CUPERTINO, Calif. , Dec. 13, 2017 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) has reported that the U.S. Food and Drug Administration ( FDA ) has accepted the New Drug Application (NDA) for RBP-7000.  RBP-7000 is an investigational, once-monthly

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Nov. 1, 2017 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2017 and provided a corporate update.

CUPERTINO, Calif. , Oct. 26, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, November 1, 2017 at 4:30 pm

CUPERTINO, Calif. , Oct. 19, 2017 /PRNewswire/ --   DURECT Corporation (Nasdaq: DRRX) today reported that PERSIST, the Phase 3 clinical trial for POSIMIR ® (SABER ® -Bupivacaine), did not meet its primary efficacy endpoint of reduction in pain on movement over the first 48 hours after surgery as

Agreement Relates to Intellectual Property for RBP-7000, Indivior's Investigational Once-Monthly Injectable Risperidone Product for Schizophrenia CUPERTINO, Calif. , Oct. 2, 2017 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced a patent purchase agreement with Indivior UK Limited

CUPERTINO, Calif. , Sept. 20, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Myriam Theeuwes has joined DURECT as Senior Vice President, Clinical Development.  Dr. Theeuwes joins DURECT from Johnson & Johnson where she spent 18 years, most recently as Compound

CUPERTINO, Calif. , Sept. 5, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming investment conferences.  James E. Brown , President and CEO, will present at the Rodman & Renshaw Global Investment Conference on Tuesday,

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Aug. 8, 2017 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2017 and provided a corporate update.   Executed a U.S.

- Statistically significant difference between ORADUR-Methylphenidate ER Capsule and placebo on SNAP-IV teacher form score - Study drug was generally safe and well tolerated CUPERTINO, Calif. , Aug. 8, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Orient Pharma Co.,

CUPERTINO, Calif. , Aug. 1, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Tuesday, August 8, 2017 at 4:30 pm Eastern

Top-Line Data on Track for Q4 2017 CUPERTINO, Calif. , June 22, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that patient enrollment has been completed in PERSIST, the pivotal Phase 3 clinical trial of POSIMIR® (SABER®-Bupivacaine), an investigational locally acting,

C UPERTINO , C alif., June 19, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the previously disclosed development and commercialization agreement with Sandoz AG , a division of Novartis (NYSE: NVS) , to develop and market in the United States DURECT's POSIMIR ® (SABER

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , May 10, 2017 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2017 and provided a corporate update.   Total revenues were $4.6 million and net

CUPERTINO, Calif. , May 8, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced a development and commercialization agreement with Sandoz AG , a division of Novartis (NYSE: NVS), to develop and market in the United States DURECT's POSIMIR ® (SABER ® -Bupivacaine), an

CUPERTINO, Calif. , May 4, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, May 10, 2017 at 4:30 pm Eastern Time

Biomarker analysis provides evidence for a potential therapeutic effect of DUR-928 in NASH CUPERTINO, Calif. , April 24, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary

EASL poster will feature data from a Phase 1b study of DUR-928 in nonalcoholic steatohepatitis (NASH) CUPERTINO, Calif. , April 17, 2017 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and

CUPERTINO, Calif. , April 3, 2017 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown , President and Chief Executive Officer, will be presenting at the H.C. Wainwright NASH Investor Conference on Monday, April 3  at 4:40 p.m.

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , March 14, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2016 and provided a corporate update.

CUPERTINO, Calif. , Feb. 24, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Tuesday, March 14, 2017 at 4:30 pm Eastern

CUPERTINO, Calif. , Jan. 30, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program.  DUR-928, our Epigenetic Regulator Program's lead product candidate, is an endogenous, small molecule, new chemical entity (NCE), which may have broad

CUPERTINO, Calif. , Oct. 31, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2016.  Total revenues were $3.7 million and net loss was $8.8 million for the three months ended September 30, 2016 as compared to total revenues of $4.7

Initial data from Phase 1b study in NASH CUPERTINO, Calif. , Oct. 31, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program including a description of data from the first cohort of a Phase 1b study with DUR-928 in patients with

CUPERTINO, Calif. , Oct. 21, 2016 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Monday, October 31, 2016 at 4:30 pm Eastern

CUPERTINO, Calif. , Sept. 26, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has received a Complete Response Letter from the U.S. Food and Drug Administration ( FDA ) for Pain Therapeutics' New Drug Application (NDA) for

CUPERTINO, Calif. , Sept. 6, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan , Chief Financial Officer, will be presenting at the Rodman & Renshaw Global Investment Conference on Monday, September 12 at 9:35 a.m.

CUPERTINO, Calif. , Aug. 1, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2016. Total revenues were $3.2 million and net loss was $9.0 million for the three months ended June 30, 2016 as compared to total revenues of $4.4 million

CUPERTINO, Calif. , July 25, 2016 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Monday, August 1, 2016 at 4:30 pm Eastern

Pain Therapeutics Announced today that an FDA Advisory Committee Meeting for REMOXY® is Not Needed and No Change to September 25, 2016 PDUFA Date CUPERTINO, Calif. , July 1, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE)

CUPERTINO, Calif. , June 28, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, will be presenting at the Cantor Fitzgerald Healthcare Conference on Tuesday, July 12 at 8:00 a.m. Eastern Time .  The conference is being held at Le Parker

CUPERTINO, Calif. , May 31, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown , President and Chief Executive Officer, will be presenting at the Jefferies Healthcare Conference on Friday, June 10 at 1:30 pm Eastern Time . The conference is being held at the

FDA's Tentative Date for Advisory Committee Meeting is August 5, 2016 and No Change to PDUFA Date of September 25, 2016 CUPERTINO, Calif. , May 19, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that an

CUPERTINO, Calif. , May 11, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced researchers will present new data around REMOXY ' s abuse-deterrent properties at the 35 th Annual Scientific Meeting of the American Pain Society (APS) meeting.  The scientific poster is titled

CUPERTINO, Calif. , May 5, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2016.  Total revenues were $3.6 million and net loss was $7.9 million for the three months ended March 31, 2016 as compared to total revenues of $4.8 million

CUPERTINO, Calif. , April 29, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the closing of an underwritten public offering of 13,800,000 shares of its common stock, offered at a price of $1.25 per share to the public, including 1,800,000 shares purchased by the underwriters

CUPERTINO, Calif. , April 28, 2016 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2016 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 5, 2016 at 4:30 pm Eastern

CUPERTINO, Calif. , April 26, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price of $1.25 per share to the public.  The gross proceeds to DURECT from this offering are

CUPERTINO, Calif. , April 25, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that it is offering, subject to market conditions, shares of its common stock in an underwritten public offering. DURECT anticipates using the net proceeds from this offering for general corporate

CUPERTINO, Calif. , April 12, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced its licensee, Pain Therapeutics (Nasdaq: PTIE), has been informed by the U.S. Food and Drug Administration ( FDA ) that the New Drug Application (NDA) for REMOXY ® , an abuse-deterrent formulation

CUPERTINO, Calif. , April 7, 2016 /PRNewswire / -- DURECT Corporation (Nasdaq: DRRX) today announced that after the PERSIST Phase 3 trial for POSIMIR ® was underway and enrolling patients at multiple sites, the Company received a letter from FDA advising the Company to make a number of amendments

CUPERTINO, Calif. , March 29, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced its licensee, Pain Therapeutics (Nasdaq: PTIE), has resubmitted the New Drug Application (NDA) for REMOXY ® (oxycodone capsules CII) to the U.S. Food and Drug Administration (FDA).   Pain

CUPERTINO, Calif. , Feb. 29, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2015 . Total revenues were $5.2 million for the three months ended December 31, 2015 and $4.3 million for the three months ended December 31

CUPERTINO, Calif. , Feb. 18, 2016 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, February 29, 2016 at 4:30 pm

CUPERTINO, Calif. , Jan. 28, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Monday, February 8 at 4:00 p.m. Eastern Time .  The conference is being held at the

Single-Ascending-Dose Study in NASH Patients CUPERTINO, Calif. , Jan. 11, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has initiated a single-ascending-dose Phase 1b clinical trial with DUR-928 in patients with nonalcoholic steatohepatitis (NASH).  DUR-928 is an

Initial Phase 1 Safety Studies Successfully Completed, Positioning for the Start of Patient Studies in 2016 CUPERTINO, Calif. , Jan. 6, 2016 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of

CUPERTINO, Calif. , Nov. 30, 2015 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan , Chief Financial Officer, will be presenting at the Oppenheimer Healthcare Conference on Tuesday, December 8 at 2:45 pm Eastern Time .  The conference is being held at the Westin

CUPERTINO, Calif. , Nov. 5, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown , President and Chief Executive Officer, will be presenting at the Stifel Nicolaus Healthcare Conference on Wednesday, November 18 at 9:30 am Eastern Time . The conference is being held

CUPERTINO, Calif. , Nov. 2, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2015.  Total revenues were $4.7 million and net loss was $6.5 million for the three months ended September 30, 2015 as compared to total revenues of $4.3

CUPERTINO, Calif. , Oct. 26, 2015 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 2, 2015 at 4:30 pm Eastern

CUPERTINO, Calif. , Oct. 15, 2015 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan , Chief Financial Officer, will be presenting at the BIO Investor Forum on Wednesday, October 21 at 9:30 a.m. Pacific time .  The conference is being held at the Parc55 Hotel in San

CUPERTINO, Calif. , Aug. 27, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences.  James E. Brown , President and CEO, will present at the Rodman & Renshaw Investment Conference on Thursday,

CUPERTINO, Calif. , Aug. 3, 2015 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2015.  Total revenues were $4.4 million and net loss was $5.5 million for the three months ended June 30, 2015 as compared to total revenues of $4.6

CUPERTINO, Calif. , July 24, 2015 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 3, 2015 at 4:30 pm Eastern

CUPERTINO, Calif. , June 29, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, will be presenting at the Cantor Fitzgerald Healthcare Conference on Wednesday, July 8 at 11:45 a.m. Eastern Time .  The conference is being held at Le Parker

CUPERTINO, Calif. , June 23, 2015 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced that, based on feedback from the FDA , it plans to conduct a new POSIDUR ™ (SABER ® -Bupivacaine) Phase 3 clinical trial consisting of approximately 300 patients undergoing laparoscopic cholecystectomy

CUPERTINO, Calif. , May 18, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has obtained positive results from a multi-dose Phase 1 clinical trial with an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program. DUR-928 is an

CUPERTINO, Calif. , April 30, 2015 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2015.  Total revenues were $4.8 million and net loss was $4.9 million for the three months ended March 31, 2015 as compared to total revenues of $6.3

CUPERTINO, Calif. , April 22, 2015 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, April 30, 2015 at 4:30 pm

CUPERTINO, Calif. , March 30, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program.  DUR-928 is an endogenous, small-molecule,

CUPERTINO, Calif. , March 2, 2015 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2014 . Total revenues were $4.3 million for the three months ended December 31, 2014 and for the three months ended December 31 , 2013.  Net

Initial Phase 1 Safety Study Successfully Completed, Building on Promising Body of Preclinical Data CUPERTINO, Calif. , March 2, 2015 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced its Epigenomic Regulator Program, and the successful completion of a Phase 1 clinical trial with

CUPERTINO, Calif. , Feb. 23, 2015 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, March 2, 2015 at 4:30 pm Eastern

CUPERTINO, Calif. , Jan. 29, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Tuesday, February 10 at 8:00 a.m. Eastern Time .  The conference is being held at the

CUPERTINO, Calif. , Dec. 16, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen the exclusive worldwide rights to develop and commercialize a sustained release product utilizing DURECT's

CUPERTINO, Calif. , Dec. 1, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan , Chief Financial Officer, will be presenting at the Oppenheimer 25 th Annual Healthcare Conference on Wednesday, December 10 at 3:55 p.m.

CUPERTINO, Calif. , Nov. 11, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced that it has received meeting minutes from its face-to-face meeting with the FDA on September 23, 2014 regarding the POSIDUR ™ program.   In the February 2014 Complete Response Letter (CRL), FDA indicated

CUPERTINO, Calif. , Nov. 3, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2014.  Total revenues were $4.3 million and net loss was $7.1 million for the three months ended September 30, 2014 ,  compared to total revenues of $3.0

CUPERTINO, Calif. , Oct. 27, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) reported today that Pfizer Inc. (NYSE: PFE) announced today that it has notified Pain Therapeutics, Inc. (Nasdaq: PTIE) that Pfizer has decided to discontinue its agreement to develop and commercialize  REMOXY ®

CUPERTINO, Calif. , Oct. 24, 2014 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 3, 2014 at 4:30 pm Eastern

CUPERTINO, Calif. , Oct. 10, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR ™ (SABER ® -Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at ANESTHESIOLOGY ™ 2014, the

CUPERTINO, Calif. , Aug. 25, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, will be presenting at the Rodman & Renshaw Investment Conference on Wednesday, September 10  at 10:25 a.m.

CUPERTINO, Calif. , Aug. 7, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2014.  Total revenues were $4.6 million and net loss was $5.5 million for the three months ended June 30, 2014 as compared to total revenues of $3.9

CUPERTINO, Calif. , July 30, 2014 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, August 7, 2014 at 4:30 pm

CUPERTINO, Calif. , June 26, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it had entered into a Loan and Security Agreement (the "Loan Agreement") with Oxford Finance LLC , pursuant to which Oxford agreed to make a term loan to the Company in the principal amount of

CUPERTINO, Calif. , June 9, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan , Chief Financial Officer, will be presenting at The 25 th Annual Wall Street Analyst Forum Institutional Investor Conference on Thursday, June 19 at 10:35 a.m.

CUPERTINO, CA, May 16, 2014 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR™ (SABER®-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at the International

CUPERTINO, Calif. , May 7, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown , President and CEO of DURECT Corporation , will be an industry speaker at the Bay Area Prescription Drug Abuse Summit on May 7, 2014 in San Francisco.  The summit is an effort to

CUPERTINO, Calif. , May 1, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2014.  Total revenues were $6.3 million and net loss was $3.6 million for the three months ended March 31, 2014 as compared to total revenues of $4.2 million

CUPERTINO, Calif. , April 23, 2014 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 1, 2014 at 4:30 pm Eastern

CUPERTINO, Calif. , April 1, 2014 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR ™ (SABER ® -Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at the 39 th Annual American

CUPERTINO, Calif. , Feb. 27, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2013 . Total revenues were $4.3 million for the three months ended December 31, 2013 as compared to $3.3 million for the three months ended

CUPERTINO, Calif., Feb. 18, 2014 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, February 27, 2014 at 4:30 pm

Company will Host Conference Call on February 13, 2014 CUPERTINO, Calif. , Feb. 12, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration ( FDA ) has issued a Complete Response Letter for POSIDUR ™ (SABER ® -Bupivacaine), an

HAYWARD, CA and CUPERTINO, CA, January 7, 2014 -- Impax Laboratories, Inc.(NASDAQ: IPXL) and DURECT Corporation (Nasdaq: DRRX) announced today that they have entered into an agreement granting Impax the exclusive worldwide rights to develop and commercialize ELADUR®, DURECT’s investigational

CUPERTINO, Calif. , Nov. 13, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the closing of an underwritten public offering of 7,142,858 shares of its common stock, offered at a price of $1.40 per share to the public.  All of the shares in the offering were sold by DURECT. 

CUPERTINO, Calif. , Nov. 8, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 7,142,858 shares of its common stock, offered at a price of $1.40 per share to the public.  The gross proceeds to DURECT from this offering are

CUPERTINO, Calif. , Nov. 7, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it is offering, subject to market conditions, shares of its common stock in an underwritten public offering. DURECT anticipates using the net proceeds from this offering for general corporate

CUPERTINO, Calif. , Nov. 4, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2013. Total revenues were $3.0 million for the three months ended September 30, 2013 as compared to $3.8 million for the three months ended September 30 ,

CUPERTINO, Calif. , Oct. 28, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 4, 2013 at 4:30 pm Eastern

CUPERTINO, Calif. , Oct. 22, 2013 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that Pfizer Inc. (NYSE: PFE) has stated that, having achieved technical milestones related to manufacturing, they will continue the development program for REMOXY ® (oxycodone) Extended-Release

Jay Shepard to join the Board effective September 26, 2013 Michael Casey to retire from the Board effective December 31, 2013 CUPERTINO, Calif. , Sept. 27, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Jay Shepard will join its Board of Directors effective September 26

CUPERTINO, Calif. , Sept. 3, 2013 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) James E.

CUPERTINO, Calif. , Aug. 5, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2013. Total revenues were $3.9 million for the three months ended June 30, 2013 as compared to $4.8 million for the three months ended June 30 , 2012.  Net

CUPERTINO, Calif. , Aug. 1, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it and its collaborator Orient PHARMA Co., Ltd. , a diversified multinational pharmaceutical, healthcare and consumer products company with headquarters in Taiwan , have selected a lead

CUPERTINO, Calif. , July 26, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 5, 2013 at 4:30 pm Eastern

CUPERTINO, Calif. , June 20, 2013 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced that the New Drug Application (NDA) for the investigational product POSIDUR (SABER-Bupivacaine) has been accepted by the U.S. Food and Drug Administration ( FDA ) indicating that the application is

CUPERTINO, Calif. , May 10, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Pfizer has provided an update on Remoxy as part of their Form 10-Q filing.  Pfizer's disclosure is as follows: "In 2005, King Pharmaceuticals, Inc.

CUPERTINO, Calif. , May 2, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2013. Total revenues were $4.2 million and net loss was $5.2 million for the three months ended March 31 , 2013.  For comparison, total GAAP revenue was $41.2

CUPERTINO, Calif. , April 24, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation 's (Nasdaq: DRRX) first quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 2, 2013 at 4:30 pm Eastern

CUPERTINO, Calif. , April 16, 2013 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for the investigational product POSIDUR (SABER ® -Bupivacaine).  POSIDUR is a post-operative pain

CUPERTINO, Calif., Feb. 28, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2012 . Total revenues were $3.3 million for the three months ended December 31, 2012 as compared to $8.9 million for the three months ended

CUPERTINO, Calif. , Feb. 22, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation 's (Nasdaq: DRRX) fourth quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, February 28, 2013 at 4:30 pm

CUPERTINO, Calif. , Feb. 5, 2013 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.  Matthew J. Hogan , Chief Financial Officer, will present at the BIO CEO & Investor Conference on Tuesday, February

CUPERTINO, Calif. , Jan. 3, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced that its licensee, Zogenix Inc. (Nasdaq: ZGNX), today reported positive single-dose pharmacokinetic (PK) results from the Phase 1 clinical trial of Relday ™ , an investigational candidate of a proprietary,

CUPERTINO, Calif. , Dec. 6, 2012 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 14 million shares of its common stock, offered at a price of $0.90 per share to the public.  The gross proceeds to DURECT from this offering are

CUPERTINO, Calif. , Nov. 13, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.  James E. Brown , President and CEO, will present at the Credit Suisse 2012 Healthcare Conference on Thursday, November

CUPERTINO, Calif. , Nov. 5, 2012 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2012 . Total revenues were $3.8 million for the three months ended September 30, 2012 as compared to $8.1 million for the three months ended

CUPERTINO, Calif. , Oct. 30, 2012 /PRNewswire/ -- In conjunction with DURECT Corporation 's (Nasdaq: DRRX) third quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 5, 2012 at 4:30 pm

CUPERTINO, Calif. , Aug. 21, 2012 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.  (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) Matt Hogan , Chief Financial Officer, will present at

CUPERTINO, Calif. , Aug. 6, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2012 . Total revenues were $4.8 million for the three months ended June 30, 2012 as compared to $7.8 million for the three months ended June 30 ,

CUPERTINO, Calif. , Aug. 6, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed its pre-NDA communications  with the United States Food and Drug Administration ( FDA ) regarding POSIDUR ™ (SABER ® -Bupivacaine).  Through this process, DURECT has received

CUPERTINO, Calif. , July 26, 2012 /PRNewswire/ -- In conjunction with DURECT Corporation 's (Nasdaq: DRRX) second quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 6, 2012 at 4:30 pm Eastern

CUPERTINO, Calif. , May 3, 2012 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2012 . Excluding the accelerated recognition of deferred revenue described below, DURECT 's reported revenues would have been $5.8 million for

New Patents Broaden and Extend Protection for REMOXY® and other ORADUR-based Opioids CUPERTINO, Calif. , May 3, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the issuance of four patents by the United States Patent and Trademark Office (USPTO) covering DURECT 's ORADUR

CUPERTINO, Calif., April 25, 2012 /PRNewswire via COMTEX/ --In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 3, 2012 at 4:30 pm

CUPERTINO, Calif. , March 29, 2012 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today reported that Hospira, Inc. has given notice that it is returning its development and commercialization rights to POSIDUR™ (SABER®-Bupivacaine) in the U.S.

CUPERTINO, Calif. , March 1, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2011 . Total revenues were $8.9 million for the three months ended December 31, 2011 , up from $8.5 million for the three months

CUPERTINO, Calif. , Feb. 24, 2012 /PRNewswire/ -- In conjunction with DURECT Corporation 's (Nasdaq: DRRX) fourth quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, March 1, 2012 at 4:30 pm

CUPERTINO, Calif. , Feb. 23, 2012 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) James E.

CUPERTINO, Calif. , Feb. 7, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Tuesday, February 14 at 10:30 a.m. Eastern Time .  The conference is being held at the

CUPERTINO, Calif. , Jan. 30, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Takeda (through Nycomed) has given notice that it is returning its development and commercialization rights to POSIDUR™ (SABER™-Bupivacaine) in Europe and their other licensed territories. 

Conference call to be held January 6 at 8:30 a.m. ET CUPERTINO, Calif. , Jan. 5, 2012 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) announced today top-line results from the U.S. pivotal Phase III clinical study for POSIDUR® known as BESST (Bupivacaine Effectiveness and Safety in SABER

CUPERTINO, Calif., Nov. 7, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) Jim Brown , President and CEO, will present at

CUPERTINO, Calif., Nov. 3, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2011 . Total revenues were $8.1 million for the three months ended September 30, 2011 and 2010.

CUPERTINO, Calif., Oct. 26, 2011 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, November 3, 2011 at

CUPERTINO, Calif., Sept. 6, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today the dosing of the last patient in the U.S. pivotal Phase III clinical study for POSIDUR® known as BESST (Bupivacaine Effectiveness and Safety in SABER trial).

CUPERTINO, Calif., Aug. 31, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) Jim Brown , President and CEO, will present at

CUPERTINO, Calif., Aug. 4, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2011 . Total revenues increased to $7.8 million for the three months ended June 30, 2011 from $7.3 million for the three months ended

CUPERTINO, Calif., July 28, 2011 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, August 4, 2011 at 4:30

Zogenix to Develop and Commercialize Proprietary Long-Acting Risperidone Formulation for Needle-Free Subcutaneous Administration Using the DosePro(R) Delivery System and DURECT's SABER(TM) Depot Technology Potential to Address $16 Billion World-Wide Antipsychotics Market SAN DIEGO and CUPERTINO,

CUPERTINO, Calif., June 24, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Pfizer Inc. (NYSE: PFE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for REMOXY®, a controlled-release

CUPERTINO, Calif., June 3, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown , President and CEO, will be presenting at the Jefferies Healthcare Conference on Tuesday, June 7 at 4:30 p.m. Eastern time . The conference is being held at the Grand Hyatt

CUPERTINO, Calif., June 2, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Joseph Stauffer , Chief Medical Officer and Executive Vice President, Corporate Strategy has resigned effective June 21, 2011 to pursue other opportunities. Dr.

CUPERTINO, Calif., May 12, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan , Chief Financial Officer, will be presenting at the UBS Global Specialty Pharmaceuticals Conference on Tuesday, May 24 at 10:00 a.m. London Time.

CUPERTINO, Calif., May 5, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2011 . Total revenues increased to $8.6 million for the three months ended March 31, 2011 from $7.7 million for the three months ended

CUPERTINO, Calif., April 28, 2011 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 5, 2011 at 4:30 pm

CUPERTINO, Calif., April 11, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today top-line results from a Phase II clinical trial in chronic low back pain for ELADUR(R) (TRANSDUR(R)-Bupivacaine), DURECT's proprietary investigational transdermal bupivacaine pain patch.

CUPERTINO, Calif., March 1, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. James E. Brown , President and Chief Executive Officer, will be presenting at the Cowen and Company 31st Annual Healthcare Conference on Monday, March 7 at 1:00 pm Eastern Time .

CUPERTINO, Calif., Feb. 24, 2011 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, March 2, 2011 at 4:30

CUPERTINO, Calif., Feb. 9, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today results from a European Phase IIb shoulder clinical trial conducted by Nycomed of POSIDUR(TM) (also known as SABER(TM)-bupivacaine or Optesia(TM) in the E.U.), a proprietary product under

Covers an Animal Health Application CUPERTINO, Calif., Feb. 8, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) today reported that its collaborator, CreoSalus, Inc., has launched commercial sales of its Food and Drug Administration (FDA) approved product known as SucroMate(TM)

CUPERTINO, Calif., Feb. 7, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Monday, February 14 at 9:30 a.m. Eastern Time .

CUPERTINO, Calif., Jan. 27, 2011 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) today reported that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for REMOXY(R) by King Pharmaceuticals, Inc.

CUPERTINO, Calif., Dec. 27, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) today reported that King Pharmaceuticals, Inc. (NYSE: KG) and Pain Therapeutics, Inc. (Nasdaq: PTIE) have announced that King has resubmitted a New Drug Application (NDA) for REMOXY(R) to the U.S.

CUPERTINO, Calif., Nov. 22, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) and Joe Stauffer (Chief Medical Officer) will be presenting at the 22nd Annual Piper Jaffray Health Care Conference on Wednesday, December 1 at

CUPERTINO, Calif., Nov. 8, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Credit Suisse 2010 Healthcare Conference on Friday, November 12 at 8:30 a.m. Pacific Time.

CUPERTINO, Calif., Nov. 3, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2010. Total revenues were $8.1 million for the three months ended September 30, 2010 compared to $8.4 million for the three months

CUPERTINO, Calif., Nov. 2, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has been awarded grants totaling $733,438 to advance our programs in post-operative pain relief, attention deficit disorder (ADHD) and chronic diseases treated with biologic agents.

CUPERTINO, Calif., Oct 27, 2010 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, November 3, 2010 at

CUPERTINO, Calif., Sep 7, 2010 (GlobeNewswire via COMTEX) -- DURECT Corporation (Nasdaq:DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences. -- Joe Stauffer, Chief Medical Officer and EVP-Corporate Strategy, will deliver a talk entitled "FDA

CUPERTINO, Calif., Aug 04, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2010. Total revenues were $7.3 million for the three months ended June 30, 2010 compared to $4.9 million for the three months ended June

CUPERTINO, Calif., July 29, 2010 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, August 4, 2010 at

CUPERTINO, Calif., July 28, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matthew J. Hogan, Chief Financial Officer, will be presenting at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on Thursday, August 5 at 1:45 p.m. Eastern Time.

CUPERTINO, Calif., July 1, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has secured a committed equity financing facility under which it may sell up to $50 million of its registered common stock to Azimuth Opportunity Ltd. for a term of 24 months.

CUPERTINO, Calif., June 16, 2010 /PRNewswire via COMTEX/ --DURECT Corporation (Nasdaq: DRRX) announced today results from a European Phase IIb hysterectomy clinical trial conducted by Nycomed of POSIDUR(TM) (also known as SABER(TM)-bupivacaine or Optesia(TM) in the E.U.), a proprietary product

CUPERTINO, Calif., June 7, 2010 /PRNewswire via COMTEX/ --In conjunction with the announcement of a POSIDUR(TM) (SABER(TM)-Bupivacaine) collaboration between DURECT Corporation (Nasdaq: DRRX) and Hospira, Inc. (NYSE: HSP), you are invited to listen to a conference call that will be broadcast live

-- Product would strengthen Hospira’s acute-care portfolio, offer novel pain treatment -- LAKE FOREST, Ill., and CUPERTINO, Calif., June 7, 2010 -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, and DURECT Corporation, a specialty pharmaceutical

CUPERTINO, Calif., June 1, 2010 /PRNewswire via COMTEX/ --DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and Chief Executive Officer, will be presenting at the Jefferies Global Life Sciences Conference on Thursday, June 10 at 10:30 a.m. Eastern Time.

CUPERTINO, Calif., May 13, 2010 /PRNewswire via COMTEX/ --DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Rodman & Renshaw Global Healthcare Conference on Monday, May 17 at 4:30 p.m. London time (11:30 am Eastern Time).

CUPERTINO, Calif., May 10, 2010 /PRNewswire via COMTEX/ --DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2010. Total revenues were $7.7 million for the three months ended March 31, 2010 and $6.2 million for the three months ended March 31,

CUPERTINO, Calif., May 4, 2010 /PRNewswire via COMTEX/ --In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, May 10, 2010 at 4:30 pm

CUPERTINO, Calif., April 7, 2010 /PRNewswire via COMTEX/ --DURECT Corporation (Nasdaq: DRRX) announced today that its licensee, King Pharmaceuticals (NYSE: KG), has begun a Phase IIb clinical trial to evaluate ELADUR(TM) (TRANSDUR(TM)-Bupivacaine) for the treatment of chronic low back pain.

CUPERTINO, Calif., March 17, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Barclays Capital Global Healthcare Conference on Wednesday, March 24 at 8:30 am Eastern Time.

CUPERTINO, Calif., March 1, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the Cowen and Company 30th Annual Healthcare Conference on Monday, March 8 at 3:15 pm Eastern Time.

CUPERTINO, Calif., Feb 24, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2009. Total revenues were $4.9 million for the three months ended December 31, 2009 and $7.7 million for the three months

CUPERTINO, Calif., Feb 22, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Nycomed and DURECT have amended the Development and License Agreement entered into between the parties in 2006 covering the development and commercialization of POSIDUR(TM) (also known

CUPERTINO, Calif., Feb 17, 2010 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, February 24, 2010 at

BESST (Bupivacaine Effectiveness and Safety in SABER(TM) Trial) Targets Post-Surgical Pain CUPERTINO, Calif., Jan 19, 2010 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has begun dosing patients in its U.S. pivotal Phase III clinical trial to evaluate

CUPERTINO, Calif., Dec 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive results from a 60 patient Phase IIb clinical trial of POSIDUR(TM), a proprietary product under development for the treatment of post-surgical pain.

CUPERTINO, Calif. , Nov. 23 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan , Chief Financial Officer, and Joe Stauffer , Chief Medical Officer, will be presenting at the 21st Annual Piper Jaffray Health Care Conference on Tuesday, December 1 at 3:30 pm

CUPERTINO, Calif., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2009. Total revenues were $8.4 million for the three months ended September 30, 2009, compared to $6.6 million for the

CUPERTINO, Calif. , Oct. 26 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, October 29, 2009 at 4:30 pm

CUPERTINO, Calif. , Sept. 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) -- Matt Hogan , Chief Financial Officer, will

CUPERTINO, Calif. , Sept. 11 /PRNewswire-FirstCall/ -- -- DURECT Corporation (Nasdaq: DRRX) today reported that it has entered into a privately negotiated transaction to sell 4,444,444 primary shares of common stock to affiliates of Venrock at a price of $2.25 per share, raising net proceeds to

CUPERTINO, Calif. , Aug. 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that it has signed an exclusive long term excipient supply agreement with respect to REMOXY(R) with King Pharmaceuticals, Inc. (NYSE: KG). This agreement stipulates the terms and conditions under

CUPERTINO, Calif., Aug 18, 2009 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has signed a development and license agreement with Orient Pharma Co., Ltd., a diversified multinational pharmaceutical, healthcare and consumer products company with

Results CUPERTINO, Calif., Aug 03, 2009 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2009. Total revenues were $4.9 million for the three months ended June 30, 2009, compared to $6.3 million for the same

CUPERTINO, Calif., July 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matthew Hogan , Chief Financial Officer, will be presenting at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on Wednesday, August 5 at 4:00 pm Eastern Time .

CUPERTINO, Calif., July 27, 2009 /PRNewswire-FirstCall via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 3, 2009

CUPERTINO, Calif., July 7 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that King Pharmaceuticals, Inc. (NYSE: KG) and Pain Therapeutics, Inc. (Nasdaq: PTIE) have announced that King met with the Food and Drug Administration (FDA) on July 2, 2009 to discuss the Complete

CUPERTINO, Calif., June 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Joseph Stauffer has joined DURECT as Chief Medical Officer and Executive Vice President, Corporate Strategy. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) "Dr.

CUPERTINO, Calif., May 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2009 . Total revenues were $6.2 million for the three months ended March 31, 2009 , compared to $6.4 million for the same period in 2008.

CUPERTINO, Calif., April 28 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, May 6, 2009 at 4:30 pm

CUPERTINO, Calif., March 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive results from a 74 patient Phase IIb clinical trial conducted by Endo Pharmaceuticals of TRANSDUR(TM)-Sufentanil, a proprietary seven day patch under development for the treatment of

CUPERTINO, Calif., March 9 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matthew Hogan , Chief Financial Officer, will be presenting at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009 at 8:00 a.m. EDT .

CUPERTINO, Calif., Feb. 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Endo Pharmaceuticals (Nasdaq: ENDP) has given notice that it is returning to us Endo's rights in the U.S. and Canada to develop and commercialize TRANSDUR(TM)-Sufentanil, a proprietary

CUPERTINO, Calif., Feb. 9 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2008 . Total revenues were $6.6 million for the three months ended December 31, 2008 and December 31, 2007 .

CUPERTINO, Calif., Feb. 2 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Monday, February 9th, 2009 at 4:30 p.m.

CUPERTINO, Calif., Dec. 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Pain Therapeutics, Inc. (Nasdaq: PTIE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for REMOXY(R), an

CUPERTINO, Calif., Nov. 26 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at the following upcoming healthcare conferences in New York, NY. -- 20th Annual Piper Jaffray Health Care Conference on Wednesday, December 3rd at 8:00

CUPERTINO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2008. Total revenues were $6.6 million for the three months ended September 30, 2008, compared to $4.9 million for the same period in

CUPERTINO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the previously announced development and license agreement with Alpharma Ireland Limited, an affiliate of Alpharma Inc. (NYSE: ALO), granting such party the exclusive worldwide rights to

CUPERTINO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at the following upcoming healthcare conferences in New York, NY. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) -- Oppenheimer 19th Annual

CUPERTINO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Monday, November 3, 2008 at 4:30 p.m.

CUPERTINO, Calif., Sept. 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into a development and license agreement with an affiliate of Alpharma Inc. (NYSE: ALO) granting such party the exclusive worldwide rights to develop and commercialize

CUPERTINO, Calif., Sept. 15 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the 2008 UBS Global Life Sciences Conference being held at the Grand Hyatt Hotel in New York. Matthew J. Hogan, Chief Financial Officer, will be presenting at the

CUPERTINO, Calif., Aug 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Pain Therapeutics (Nasdaq: PTIE), its licensee, has submitted an Investigational New Drug (IND) application to the U.S.

CUPERTINO, Calif., Aug. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) of REMOXY(R) and granted Priority Review. The FDA typically grants Priority Review to drug candidates

CUPERTINO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2008. Total revenues were $6.3 million for the three months ended June 30, 2008, compared to $13.4 million for the same period in 2007.

CUPERTINO, Calif., July 30 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Wednesday, August 6, 2008 at 9:00 a.m.

CUPERTINO, CA, June 30, 2008 / PRNewswire-First Call via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the US Food and Drug Administration (FDA) has granted to DURECT orphan drug designation for bupivacaine for relief of persistent pain associated with post-herpetic neuralgia

CUPERTINO, Calif., June 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the remaining $23.6 million in 6.25% Convertible Notes had been exchanged by the holders at their maturity date into approximately 7.5 million shares, per the original terms of the indenture.

CUPERTINO, Calif., June 10 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that a New Drug Application (NDA) for Remoxy(TM) (ORADUR(TM)-based oxycodone) has been submitted to the U.S. Food and Drug Administration (FDA). Remoxy, an investigational drug, is a long acting

CUPERTINO, Calif., June 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming life sciences conferences in New York, NY. -- Needham & Company's Biotechnology and Medical Technology Conference on Thursday, June 12th at

CUPERTINO, Calif., May 21 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference being held at the Waldorf Hilton Hotel in London. Matthew J.

CUPERTINO, Calif., May 7 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2008. Total revenues were $6.4 million for the three months ended March 31, 2008, compared to $5.7 million for the same period in 2007.

CUPERTINO, Calif., April 29 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Wednesday, May 7th, 2008 at 4:30 p.m.

CUPERTINO, Calif., April 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James Brown, President and Chief Executive Officer, will be presenting at the Morgan Stanley 2008 Global Healthcare Unplugged Conference on April 30, 2008 at 8:30 a.m. ET.

CUPERTINO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Endo Pharmaceuticals has stated that it intends to return the rights to CHRONOGESIC(R) licensed from DURECT Corporation for the U.S. and Canada.

CUPERTINO, Calif., March 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James Brown, President and Chief Executive Officer, will be presenting at the Cowen and Company 28th Annual Healthcare Conference on March 17, 2008 at 4:00 p.m. EST.

CUPERTINO, Calif., Feb. 29 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James Brown, President and Chief Executive Officer, will be presenting at the SIGnificant Investment Options in Healthcare conference hosted by Susquehanna Financial Group on Tuesday, March

CUPERTINO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2007. Total revenues were $6.6 million for the three months ended December 31, 2007, compared to $5.4 million for the same period

CUPERTINO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matthew J. Hogan, Chief Financial Officer, will be presenting at the BIO CEO and Investor Conference to be held at the Waldorf Astoria Hotel in New York on February 11, 2008 at 11:45 a.m.

CUPERTINO, Calif., Jan. 31 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2007 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Wednesday, February 6, 2008 at 9:00

CUPERTINO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive results from a Phase IIa clinical trial for ELADUR(TM), DURECT's proprietary investigational transdermal pain patch. In this study of patients suffering from post-herpetic neuralgia,

CUPERTINO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the pivotal Phase III trial for Remoxy had successfully met its primary endpoint (p (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) "These positive clinical trial results

CUPERTINO, Calif., Dec. 4 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview and update at two upcoming life sciences conferences in New York, NY. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) -- NYSSA Biotech &

CUPERTINO, Calif., Nov. 20 /PRNewswire-FirstCall/ -- via COMTEX -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview and update at the 19th Annual Piper Jaffray Health Care Conference on Tuesday, November 27, 2007 at 4:00 p.m.

CUPERTINO, Calif., Nov. 1 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2007. Total revenues were $4.9 million for the three months ended September 30, 2007, compared to $5.1 million for the same period in

CUPERTINO, Calif., Nov 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview and update at two upcoming life sciences conferences in New York, NY. -- CIBC World Markets 18th Annual Healthcare Conference

CUPERTINO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2007 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Thursday, November 1, 2007 at 4:30 p.m.

CUPERTINO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will be hosting an Analyst Event in New York on October 17, 2007 at 12:00 p.m. Eastern Time. A live audio webcast of the presentation will begin at 12:30 p.m.

CUPERTINO, Calif., Oct. 4 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the 2007 BIO Investor Forum to be held at the Palace Hotel in San Francisco on October 11, 2007 at 10:30 a.m. Pacific Time.

CUPERTINO, Calif., Sept. 20 /PRNewswire-FirstCall/-- DURECT Corporation (Nasdaq: DRRX) announced today that James Brown, President and CEO, will present at the UBS Global Life Sciences Conference in New York on September 27, 2007 at 1:30 p.m. Eastern Time.

CUPERTINO, Calif., Sept. 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Felix Theeuwes, Chairman and CSO, will present at the 4th annual Merriman Curhan Ford & Co. Investor Summit on September 17, 2007 at 11:45 a.m. Pacific Time.

CUPERTINO, Calif., Aug. 29 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the NewsMakers in the Biotech Industry Investment Conference to be held in New York City on September 6, 2007 at 11:30 a.m.

CUPERTINO, Calif., Aug 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2007. Total revenues were $13.4 million for the three months ended June 30, 2007, compared to $6.1 million for

CUPERTINO, Calif., July 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2007 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Tuesday,

Phase IIb Trial Achieves Statistically Significant Reductions in Pain and Total Consumption of Supplemental Opioid Analgesic Medications Versus Placebo CUPERTINO, Calif., July 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive results from a 122 patient Phase

CUPERTINO, Calif., July 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that patient recruitment has been completed in the pivotal Phase III study with Remoxy(TM), an abuse resistant pain medicine under development based on DURECT's patented ORADUR(TM) technology

CUPERTINO, CA, June 27, 2007/ PRNewswire-First Call via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Endo Pharmaceuticals Inc. (Nasdaq: ENDP) has commenced its Phase II clinical program designed to evaluate the conversion of patients being treated with various opioids to

CUPERTINO, Calif., June 21, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Jefferies Healthcare Conference being held in New York City. Matthew J. Hogan, Chief Financial Officer, will be presenting at the

CUPERTINO, Calif., June 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Sixth Annual Biotechnology and Medical Technology Conference being held at the New York Palace Hotel in New York City. Matthew J.

CUPERTINO, Calif., May 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Voyager Pharmaceutical has provided its shareholders with an update on its truncated Phase 3 clinical trial for Memryte, an investigational drug for the treatment of Alzheimer's disease.

CUPERTINO, Calif., May 8 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it would present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference to be held on May 14-15 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. James E.

CUPERTINO, Calif., May 7 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2007. Total revenues were $5.7 million for the three months ended March 31, 2007, compared to $5.2 million for the same period in 2006.

CUPERTINO, Calif., May 1 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the 2007 UBS Global Generic and Specialty Pharmaceuticals Conference being held at the Grand Hyatt Hotel in New York City. Matthew J.

CUPERTINO, Calif., April 30 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2007 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Monday, May 7th 2007 at 4:30 p.m. EDT.

CUPERTINO, Calif., April 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC Biotechnology & Specialty Pharmaceuticals Conference being held at the Millenium Broadway Hotel in New York City. Matthew J.

CUPERTINO, Calif., Feb. 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at three upcoming life sciences conferences in New York, NY. "SIGnificant Investment Options In Healthcare" conference, sponsored by Susquehanna

CUPERTINO, Calif., Feb. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the BIO CEO Investor Conference. The conference is being held at The Waldorf Hotel in New York, NY. James E. Brown, DVM, President and CEO, will be presenting at the

CUPERTINO, Calif., Feb. 8 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2006. Total revenues were $5.4 million for the three months ended December 31, 2006, compared to $5.8 million for the same period

CUPERTINO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that we have entered into a long term manufacturing and supply agreement with Corium International, Inc. for TRANSDUR(TM)-Bupivacaine, a transdermal pain patch under development for patients

CUPERTINO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter and year-end 2006 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, February 8th,

CUPERTINO, Calif., Jan. 29 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that we have entered into a long term manufacturing and supply agreement with Hospira Worldwide, Inc. ("Hospira") (NYSE: HSP) for POSIDUR(TM), DURECT's post-surgical pain management

CUPERTINO, Calif., Jan. 24 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has amended its development and commercialization agreement with Voyager Pharmaceutical Corporation governing Memryte(TM), an investigational drug under development for the treatment of

CUPERTINO, Calif., Jan 03, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) today announced that we have started Phase II dosing in the U.S. under an FDA-accepted Investigational New Drug (IND) application for TRANSDUR(TM)-Bupivacaine (DUR-843), a transdermal

CUPERTINO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Terrence F. Blaschke, M.D. has joined its Board of Directors. Dr. Blaschke has served on the faculty of Stanford University for over 30 years and is Professor of Medicine and Molecular

CUPERTINO, Calif., Dec. 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has successfully completed Phase I clinical trials with a new product, DUR-843, which is intended to treat a persistent pain condition. We believe that the persistent pain market remains

CUPERTINO, Calif., Nov. 30 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported positive results from a Phase I clinical trial evaluating an abuse-resistant opioid pain drug candidate based on DURECT's patented ORADUR(TM) technology.

CUPERTINO, Calif., Nov. 29 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today the signing of a collaboration agreement with Nycomed, a privately held European pharmaceutical company headquartered in Denmark, whereby the companies will jointly develop DURECT's POSIDUR(TM)

CUPERTINO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2006. Total revenues were $5.1 million for the three months ended September 30, 2006, compared to $8.6 million for the same period in

CUPERTINO, Calif., Oct. 31 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at three upcoming life sciences conferences in New York, NY. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) Susquehanna International

CUPERTINO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2006 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Friday, November 3rd, 2006 at 8:30 AM

CUPERTINO, Calif., Oct. 19 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Voyager Pharmaceutical has informed DURECT that Voyager is ending its Phase III clinical trials for Memryte(TM) for the treatment of Alzheimer's Disease in order to get an earlier look at

CUPERTINO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at the BIO InvestorForum 2006 conference. The conference is being held at The Palace Hotel in San Francisco, CA. Dr. James E.

CUPERTINO, Calif., Sept. 21 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the UBS Global Life Sciences Conference. The conference is taking place September 25-28th at The Grand Hyatt Hotel in New York City, New York. Dr. James E.

CUPERTINO, Calif., Sept. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals company, announced today that Matthew J. Hogan has joined the Company as Chief Financial Officer. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) "DURECT is

CUPERTINO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at the Securities Research Associates Technology Conference on Monday, August 7th at 8:40 a.m. PST. The conference is taking place at the Westin St.

CUPERTINO, Calif., Aug 02, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) reported today the initiation of a Phase I clinical trial for a new ORADUR-based opioid drug candidate. This new drug candidate is the second ORADUR-based opioid drug to undergo

CUPERTINO, Calif., July 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2006. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended June 30, 2006 was $8.7

CUPERTINO, Calif., July 19 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2006 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, July 27th, 2006 at 4:30 p.m.

CUPERTINO, Calif., July 10 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at two upcoming life sciences conferences. Leerink Swann & Company/MEDA Corp Pain Roundtable Conference: Monday, July 10, 2006 at the Le Parker Meridien,

CUPERTINO, Calif., June 23 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at the Jefferies Life Sciences Conference on Tuesday, June 27th at 9:00 a.m. EST. The conference is taking place at The Mandarin Oriental Hotel in New

CUPERTINO, Calif., June 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at the Needham & Company, LLC's Fifth Annual Biotechnology and Medical Technology Conference on Wednesday, June 14th at 8:30 a.m. EST.

CUPERTINO, Calif., May 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on Tuesday, May 16th at 2:40 p.m. CET. The conference is taking place at Le Meridien Beach

CUPERTINO, Calif., May 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) reported today that a pivotal Phase III program has been initiated for Remoxy(TM), an abuse-resistant pain medicine under development based on DURECT's patented ORADUR(TM) technology incorporating the opioid

CUPERTINO, Calif., May 2 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2006. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended March 31, 2006 was $6.3

CUPERTINO, Calif, May 2 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals company, announced today that Peter J. Langecker, M.D., Ph.D. has joined the Company as Chief Medical Officer. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

CUPERTINO, Calif., April 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals company, provided an update on its post-operative pain relief depot, SABER(TM)-Bupivacaine program. DURECT announced results from its Phase II Australian clinical study in

CUPERTINO, Calif., April 25, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2006 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Tuesday,

CUPERTINO, Calif., April 19 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the UBS Global Specialty Pharmaceuticals Conference. The conference is taking place April 24 - 25th at The Grand Hyatt Hotel in New York City, New York. Schond L.

CUPERTINO, Calif., March 30 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is taking place April 4-5th at The Millennium Broadway Hotel in New York

CUPERTINO, Calif., Feb. 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) reported today that Remoxy(TM), an abuse-resistant pain medicine under development based on DURECT's patented ORADUR(TM) technology incorporating the opioid oxycodone has successfully completed a Special Protocol

CUPERTINO, Calif., Feb. 10 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the BIO CEO Investor Conference. The conference is being held at The Waldorf Hotel in New York, NY. Schond L. Greenway, Vice President, Investor Relations and Strategic

CUPERTINO, Calif., Feb. 8 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today its financial results for the three months and year ended December 31, 2005. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) Our net loss for the three months ended December 31, 2005

CUPERTINO, Calif., Feb. 8 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today announced its intended development milestones for fiscal year 2006. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) "These announced milestones are intended to assist the investment community

CUPERTINO, Calif., Jan. 26 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical company, announced today that it plans to expand its worldwide development program for its post-operative pain relief depot, SABER(TM)-Bupivacaine, by initiating additional

CUPERTINO, Calif., Jan. 23 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter and year-end 2005 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, February 8th,

CUPERTINO, Calif., Jan 06, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of four executives to its senior management team. Harry Guy has joined DURECT as Vice President of Engineering and Safety.

CUPERTINO, Calif., Jan. 3 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the JPMorgan 24th Annual Healthcare Conference. The conference is being held at The Westin St. Francis Hotel in San Francisco. Dr. James E.

CUPERTINO, Calif., Dec 26, 2005 /PRNewswire via COMTEX News Network/ -- CUPERTINO, Calif., Dec. 26 /PRNewswire-FirstCall/--DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals company, announced today positive preliminary results from a multiple dose clinical study in chronic

CUPERTINO, Calif., Nov. 15 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the underwriters of its recent public offering of 7,400,000 shares of its common stock have exercised in full their over-allotment option to purchase an additional 1,110,000 shares of common

CUPERTINO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced the validation of the commercial potential of its ORADUR(TM) sustained release oral gel-cap technology with the recently announced strategic alliance to develop and commercialize Remoxy(TM), an

CUPERTINO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Sixteenth Annual CIBC Healthcare Conference. The conference is being held at The Waldorf-Astoria Hotel in New York, New York. Dr. James E.

CUPERTINO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference. The conference is being held at The Waldorf Astoria in New York, NY. Dr. James E.

CUPERTINO, Calif., Nov. 2 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today the pricing of its public offering of 7,400,000 shares of its common stock, including 32,256 shares of common stock offered by certain selling stockholders, at $5.00 per share.

CUPERTINO, Calif., Oct 27, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) announced today a proposed offering of 7,400,000 shares of its common stock and 32,256 shares of common stock owned by certain selling stockholders.

CUPERTINO, Calif., Oct 18, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive preliminary results from the Phase II dose escalation study (Cohorts 1-3) in hernia patients in Australia for DURECT's post-operative pain relief depot,

CUPERTINO, Calif., Oct. 14 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical company announced today the initiation of dosing for the Phase III clinical studies for the DURIN(TM)-based leuprolide program under development with Voyager Pharmaceuticals

CUPERTINO, Calif., Oct. 13 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2005. DURECT's net loss for the three months ended September 30, 2005 was $3.0 million or 6 cents per share, compared to a net loss of

CUPERTINO, Calif., Oct 07, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2005 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday,

CUPERTINO, Calif., Sept 21, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical company, announced today it plans to present preliminary cohort 3 clinical data from its Phase II study for DURECT's post-operative pain relief

CUPERTINO, Calif., Sept. 19 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX - News), an emerging specialty pharmaceutical company, announced today the completion of dosing in the third and final cohort of the Phase II dose escalation study in hernia patients in Australia for DURECT's

CUPERTINO, Calif., Sept. 9 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical company, announced today that Pain Therapeutics, Inc. has achieved positive Phase III clinical results for Remoxy(TM), a novel long-acting, abuse-deterrent oral formulation

CUPERTINO, Calif., Aug. 8 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Summer Tech Fest 2005 Investor Conference Hosted by C.E. Unterberg Towbin and Security Research Associates. The conference is being held at the Omni Hotel in San

CUPERTINO, Calif., Aug. 1 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill Annual Summer Seminar. The conference is being held at the Boston Marriott Long Wharf Hotel. James E.

CUPERTINO, Calif., July 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2005. DURECT's net loss for the three months ended June 30, 2005 was $3.6 million or 7 cents per share, compared to a net loss of $7.4 million

CUPERTINO, Calif., July 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the Company has entered into a privately negotiated agreement with a holder of its 6.25% Convertible Subordinated Notes, due June 2008, to exchange up to $5 million in principal amount of

CUPERTINO, Calif., July 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the C. E. Unterberg, Towbin Emerging Growth Conference. The conference is being held at The Mandarin Oriental Hotel in New York, NY. Dr. James E.

CUPERTINO, Calif., July 11, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today the start of dosing in the third and final cohort of the Phase II dose escalation study in hernia patients in Australia for DURECT's post-operative pain relief depot,

CUPERTINO, Calif., July 8, 2005 /PRNewswire-FirstCall via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2005 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Friday, July 22, 2005

CUPERTINO, Calif., June 20 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive preliminary results from the second cohort of an on-going Phase II clinical study in hernia patients for DURECT's post-operative pain relief depot product candidate,

CUPERTINO, Calif., May 24 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Friedman Billings Ramsey 9th Annual Growth Investor Conference. The conference is taking place June 1-2nd at The Millennium Broadway Hotel in New York City, New York.

CUPERTINO, Calif., May 3 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2005. DURECT's net loss for the three months ended March 31, 2005 was $5.4 million or 10 cents per share, compared to a net loss of $6.0

CUPERTINO, Calif., April 19 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2005 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Tuesday, May 3, 2005 at 4:30 p.m. EDT.

CUPERTINO, Calif., April 18, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that effective April 14, 2005, the company has appointed Simon X. Benito to its Board of Directors to replace Albert L. Zesiger who is stepping down as a member of the Board of

CUPERTINO, Calif., April 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today the expected departure of Thomas A. Schreck, Co-Founder and Chief Financial Officer on April 30, 2005, to pursue other interests in private ventures in the life sciences sector. Mr.

CUPERTINO, Calif., March 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is taking place April 4-5th at The Millennium Broadway

CUPERTINO, Calif., March 14, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has signed an agreement with Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP), that will give Endo the exclusive

CUPERTINO, Calif., Feb 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Security Research Associates Spring Technology & Life Sciences Investor Conference at the Campton Place Hotel in San Francisco. Dr. James E.

CUPERTINO, Calif., Feb. 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals systems company, today announced the initiation of the Phase II program for DURECT's TRANSDUR(TM)-based sufentanil patch. Based on the results of our Phase I trial for our

CUPERTINO, Calif., Feb 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today its financial results for the three months and year ended December 31, 2004. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) Our net loss for the three months ended

CUPERTINO, Calif., Feb. 10 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals systems company, today announced the completion of dosing of the Phase I pharmacokinetic study for DURECT's TRANSDUR(TM)-based sufentanil patch.

CUPERTINO, Calif., and RALEIGH, N.C., Jan 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical systems company, and Voyager Pharmaceutical Corporation, a privately held specialty pharmaceutical company focused on diseases of aging,

CUPERTINO, Calif., Jan. 25 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Paula Mendenhall has joined DURECT as Senior Vice President of Operations. Dr. Mendenhall has over 30 years of pharmaceutical experience covering areas such as research, manufacturing and

CUPERTINO, Calif., Jan. 20 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter and year-end 2004 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, February 10,

CUPERTINO, Calif., Jan. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today announced its intended clinical and corporate milestones for the fiscal year 2005. "These announced milestones are intended to assist the investment community to track our progress throughout the coming

CUPERTINO, Calif., Jan. 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the Company will host a reception to provide an update to its development pipeline and program objectives for fiscal year 2005. The presentation will be held at the Weinstein Gallery in San

CUPERTINO, Calif., Dec. 23 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical systems company, announced today the initiation of Phase III clinical testing for Remoxy(TM), a novel long-acting, abuse-deterrent oral formulation of oxycodone based on

CUPERTINO, Calif., Dec. 20 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical systems company, and Voyager Pharmaceutical Corporation, a privately held specialty pharmaceutical company focused on diseases of aging, announced today the acceptance of the

CUPERTINO, Calif., Nov 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Lazard First Annual Life Sciences Conference. The conference is being held at Mandarin Oriental Hotel in New York, New York. Dr.

CUPERTINO, Calif., Nov 4, 2004 (PRNewswire-FirstCall via COMTEX) -- DURECT Corporation announced today that it will present at the Fifteenth Annual CIBC Healthcare Conference. The conference is being held at The Plaza Hotel in New York, New York. Dr. James E.

CUPERTINO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2004 and an update on its development programs. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) Our net loss for the three

CUPERTINO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today the initiation of a Phase II clinical study for its post-operative pain relief depot (SABER-bupivacaine), a sustained-release formulation of a local anesthetic using the Company's SABER(TM) drug

Patch to be Highlighted at ASA 2004 Annual Meeting CUPERTINO, Calif., Oct. 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today announced the initiation of a phase I clinical trial for a new proprietary transdermal sufentanil product. The trial consists of a pharmacokinetic study in

CUPERTINO, Calif., Oct 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the C. E. Unterberg, Towbin Specialty Pharmaceutical Conference. The conference is being held at The Palace Hotel in New York, NY. Dr. James E.

CUPERTINO, Calif., Oct. 21 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference. The conference is being held at The Waldorf Astoria in New York, NY. Dr. James E.

CUPERTINO, Calif., Oct. 18 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2004 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, October 25, 2004 at 4:30 p.m.

CUPERTINO, Calif., Oct. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the HealthpointCapital Biomaterials Summit. The conference is being held at the Omni Berkshire Place in New York City, NY. Thomas A.

CUPERTINO, Calif., Oct. 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the BIO Emerging Company Investor Forum. The conference is being held at The Palace Hotel in San Francisco, CA. Dr. Felix Theeuwes, Chairman and Chief Scientific Officer,

CUPERTINO, Calif., Sep 16, 2004 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the First Annual Merriman Curhan Ford & Co. Investor Summit. The conference is being held at The Mark Hopkins Hotel in San Francisco, CA. Dr. James E.

CUPERTINO, Calif., Aug. 9 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Halpern Capital Summer Growth Stock Conference. The conference is being held at The Campton Place Hotel in San Francisco, CA. Dr.

CUPERTINO, Calif., Aug 2, 2004 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill - 24th Annual Summer Seminar. The conference is being held at the Boston Marriott Long Wharf Hotel. Thomas A.

CUPERTINO, Calif., July 21 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2004 and an update on its development programs. Our net loss for the three months ended June 30, 2004 was $7.4 million or 14 cents per share,

CUPERTINO, Calif., July 15 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2004 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, July 21, 2004 at 4:30 p.m.

CUPERTINO, Calif., July 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced the advancement of its ORADUR(TM) sustained release oral gel-cap technology (formerly referred to as the SABER(TM) oral gel-cap technology) with positive human clinical results for Remoxy(TM).

CUPERTINO, Calif., and VALENCIA, Calif., June 21 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) and NeuroSystec Corporation ("NeuroSystec"), a privately held company located in Valencia, CA, announced today that they have signed an exclusive agreement to develop, market and sell

CUPERTINO, Calif., May 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Rodman & Renshaw Techvest Global Healthcare Conference at 3:30 PM local time (10:30 AM, Eastern Daylight Time) on Wednesday, May 12, 2004 in London, England.

CUPERTINO, Calif., April 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is taking place April 27-28th at The Millennium Broadway Hotel in New

CUPERTINO, Calif., April 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2004. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended March 31, 2004 was $6.0

CUPERTINO, Calif., Apr 14, 2004 /PRNewswire-FirstCall via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2004 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, April 22, 2004

CUPERTINO, Calif., Mar 23, 2004 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Michael D. Casey to its Board of Directors to replace John L. Doyle who left the Board in November 2003. The appointment of Mr.

CUPERTINO, Calif., Feb. 24 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Smith Barney Citigroup Specialty Pharmaceuticals Conference. The conference is taking place February 24-25th at The Marriott East Side Hotel in New York City, New York.

CUPERTINO, Calif., Feb. 13 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Su IL Yum has been promoted to Senior Vice President of Engineering. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) "We are very fortunate to have Su IL to help us through

CUPERTINO, Calif., Feb. 10 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today its financial results for the three months and year ended December 31, 2003. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended December

CUPERTINO, Calif., Jan. 27 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter and year end 2003 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Tuesday, February 10, 2004

CUPERTINO, Calif., Jan. 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the JPMorgan H&Q 22nd Annual Healthcare Conference. The conference is taking place January 12-15th at The Westin St. Francis Hotel in San Francisco. Dr. James E.

CUPERTINO, Calif., Nov. 7 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference. The conference is being held at The Plaza Hotel in New York City. James E.

CUPERTINO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today its financial results for the three months ended September 30, 2003. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended September 30, 2003

CUPERTINO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the Company has completed its first study in humans with its post-operative pain relief depot product. DURECT's post-operative pain relief depot product, a sustained release injectable using

CUPERTINO, Calif., Oct. 20 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2003 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, November 6, 2003 at 4:30 p.m.

CUPERTINO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has received data from a preclinical animal test with its CHRONOGESIC(R) (sufentanil) Pain Therapy Product which indicate that a small number of units (less than 2% in total) utilizing the

CUPERTINO, Calif., Oct 9, 2003 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has initiated manufacture of clinical product for its anticipated pharmacokinetic study and other initial clinical studies in the Phase III program for its CHRONOGESIC(R)

CUPERTINO, Calif., Sept. 23 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the company has appointed Jon S. Saxe to its Board of Directors to replace James R. Butler who stepped down as a member of the Board of Directors in June 2003. Mr.

CUPERTINO, Calif., Sep 3, 2003 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Thomas Weisel Partners Annual Healthcare Conference. The conference is being held at the Four Seasons Hotel in Boston, MA. James E.

CUPERTINO, Calif., Sep 2, 2003 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed validation of the terminal sterilization manufacturing process for its CHRONOGESIC (sufentanil) Pain Therapy product.

CUPERTINO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill -- 23rd Annual Summer Seminar. The conference is being held at the Boston Marriott Long Wharf Hotel. James E.

CUPERTINO, Calif., Jul 24, 2003 /PRNewswire-FirstCall via Comtex/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2003. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended June 30,

CUPERTINO, Calif., Jul 11, 2003 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the initial purchaser of $50 million of its 6.25% Convertible Notes due 2008 has elected to exercise its option to purchase an additional $10 million principal amount of such

CUPERTINO, Calif., July 11 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2003 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, July 24, 2003 at 4:30 p.m.

CUPERTINO, Calif., June 13 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it agreed to privately place $50 million aggregate principal amount of Convertible Notes due 2008. These Notes will be convertible into DURECT Corporation common stock at a conversion price

CUPERTINO, Calif., June 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it proposes to offer a new issue of $50 million of Convertible Notes due 2008 through a Rule 144A offering to qualified institutional buyers. These notes will be convertible into DURECT

CUPERTINO, Calif., June 10 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the Company has commenced clinical testing of its post-operative pain relief depot product. DURECT's post-operative pain relief depot product, a sustained release injectible using the

CUPERTINO, Calif., May 15, 2003 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Friedman Billings Ramsey 7th Annual Technology & Growth Investor Conference. The conference is being held at The Millennium Hotel in New York City.

CUPERTINO, Calif., April 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2003. DURECT's net loss for the three months ended March 31, 2003 was $5.9 million or 12 cents per share, compared to $9.7 million or 20

CUPERTINO, Calif., April 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference. The conference is being held at The Millennium Hotel in New York City. James E.

CUPERTINO, Calif., April 15 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2003 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, April 28, 2003 at 4:30 p.m.

CUPERTINO, Calif., Jan. 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2002. DURECT's net loss for the three months ended December 31, 2002 was $8.5 million or 17 cents per share, compared to $10.1

CUPERTINO, Calif., Jan. 15 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter and year end 2002 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Tuesday, January 28, 2003

SOUTH SAN FRANCISCO, Calif. and CUPERTINO, Calif., Jan. 14 /PRNewswire- FirstCall/ -- Pain Therapeutics, Inc. (Nasdaq: PTIE) and DURECT Corporation (Nasdaq: DRRX) today announced they have signed an exclusive licensing agreement to formulate certain long-acting opioid drugs.

CUPERTINO, Calif., Jan. 2 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the JPMorgan H&Q 21st Annual Healthcare Conference. The conference is taking place January 6-9th at The Westin St. Francis Hotel in San Francisco. Dr. James E.

CUPERTINO, Calif., Dec. 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the company has appointed David R. Hoffmann to its Board of Directors to replace Matthew V. McPherron who is stepping down as a member of the Board of Directors.

CUPERTINO, Calif., Nov. 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it is reducing operating expenses in accordance with the Company's overall corporate objectives for the fiscal year 2003. DURECT's long-term strategy and business plan remain on track.

ZUG, Switzerland and CUPERTINO, Calif., Nov. 19 /PRNewswire-FirstCall/ -- BioPartners, a global biopharmaceuticals company and one of the leaders in the emerging field of competitively priced multi-source biopharmaceuticals, has signed an exclusive agreement with DURECT Corporation (Nasdaq: DRRX),

CUPERTINO, Calif., Nov. 14 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) and Thorn BioScience LLC announced today that the two companies have expanded their agreement for the development and commercialization of veterinary products for reproductive indications using DURECT's SABER(TM)

CUPERTINO, Calif., Nov. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2002. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended September 30, 2002 was

CUPERTINO, Calif., Nov. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has amended its development and commercialization agreement with ALZA Corporation under which DURECT holds exclusive rights to develop, commercialize and manufacture products using ALZA's

CUPERTINO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will postpone its third quarter financial results press release and conference call to Tuesday, November 12th, 2002. The earnings release is postponed due to the announcement today by

CHADDS FORD, Pa. and CUPERTINO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP) and DURECT Corporation (Nasdaq: DRRX), announced today that they have signed an agreement to collaborate on the development and commercialization of DURECT's CHRONOGESIC(TM)

CUPERTINO, Calif., Oct 30, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets 13th Annual Health Care Conference. The conference is being held at The Plaza Hotel in New York City. Dr. James E.

CUPERTINO, Calif., Oct 16, 2002 /PRNewswire-FirstCall via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, November 11th, 2002

CUPERTINO, Calif., Oct 4, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the UBS Warburg Global Life Sciences Conference. The conference is being held at The Plaza Hotel in New York City. Thomas A.

CUPERTINO, Calif., Aug 26, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that, following discussions between DURECT and the FDA on DURECT's on-going Phase III clinical trial for the CHRONOGESIC(TM) (sufentanil) Pain Therapy System, the FDA has requested

CUPERTINO, Calif., Aug 5, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill - 22nd Annual Summer Seminar. The conference is being held at The Boston Marriott Long Wharf Hotel. Dr. James E.

CUPERTINO, Calif., Jul 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2002. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT's net loss for the three months ended June 30,

CUPERTINO, Calif., Jul 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) and Voyager Pharmaceutical Corporation announced today that the two companies have signed a development and commercialization agreement to develop Voyager's patented product, using leuprolide

CUPERTINO, Calif., Jul 9, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has begun dosing of patients in the first clinical trial of its pivotal Phase III program for the CHRONOGESIC(TM) (sufentanil) Pain Therapy System.

CUPERTINO, Calif., Jul 8, 2002 /PRNewswire-FirstCall via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, July 29, 2002 at 4:30

CUPERTINO, Calif., Jun 11, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Goldman Sachs Twenty - Third Annual Global Healthcare Conference. The conference is being held at The Ritz - Carlton, Laguna Niguel in California. Dr.

CUPERTINO, Calif., Jun 5, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the UBS Warburg Global Specialty Pharmaceuticals Conference. The conference is taking place June 5-6, 2002 at the Grand Hyatt New York. Thomas A.

CUPERTINO, Calif., Apr 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is taking place May 1-2, 2002 at The Millennium Hotel in

CUPERTINO, Calif., Apr 24, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2002. DURECT's net loss for the three months ended March 31, 2002 was $9.7 million or 20 cents per share, compared to $4.9

CUPERTINO, Calif., Apr 8, 2002 (BUSINESS WIRE) -- In conjunction with DURECT Corporation's (Nasdaq:DRRX) first quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, April 24, 2002 at 4:30 p.m.

CUPERTINO, Calif., Apr 2, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has filed an Investigational New Drug application to investigate the delivery of cromolyn sodium for the treatment of asthma.

CUPERTINO, Calif., Mar 27, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today a collaboration with Cardinal Health (NYSE: CAH) Pharmaceutical Technologies and Services Center, Inc. to explore the feasibility of producing long acting soft gelatin based oral

CUPERTINO, Calif., Mar 18, 2002 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today the results from a pilot Phase III clinical study for its lead product in development, the CHRONOGESIC(TM) (sufentanil) Pain Therapy System for the treatment of chronic pain.

CUPERTINO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2001. The Company's net loss attributable to common stockholders for the three months ended December 31, 2001 was $10.1 million

CUPERTINO, Calif., Jan. 23 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it is sponsoring a symposium on novel drug delivery technologies at the 45th Annual Meeting of the Western Pharmacology Society (WPS) being held at the Hotel El Cid in Mazatlan, Sinaloa,

CUPERTINO, Calif., Jan 14, 2002 (BUSINESS WIRE) -- In conjunction with DURECT Corporation's (NASDAQ:DRRX) fourth quarter and year end 2001 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, January 30, 2002

CUPERTINO, Calif., Jan 4, 2002 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the JPMorgan H&Q 20th Annual Healthcare Conference. The conference is taking place January 7-10th at The Westin St. Francis Hotel in San Francisco. James E.

CUPERTINO, Calif., Nov 16, 2001 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that ALZA Corporation has exercised its option to allow ALZA and Janssen Pharmaceutica Products, L.P., the right to begin negotiations for exclusive sales and marketing rights to DURECT's

CUPERTINO, Calif., Nov. 1 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Twelfth Annual Health Care Conference. The conference is taking place November 5-7 at The Plaza in New York City. Thomas A.

CUPERTINO, Calif., Nov. 1 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced during its third quarter financial results conference call yesterday that the company has commenced its Phase III program for Chronogesic(TM), for the treatment of chronic pain.

CUPERTINO, Calif., Oct. 31 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2001. The company's net loss attributable to common stockholders for the three months ended September 30, 2001 was $8.9 million or 19 cents per

CUPERTINO, Calif., Oct 25, 2001 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced yesterday research results showing in animal models that new blood vessels are formed and that blood flow to an ischemic heart can be restored following targeted delivery of fibroblast growth

CUPERTINO, Calif., Oct 16, 2001 /PRNewswire via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present on technologies for targeted drug delivery at the Techvest 3rd Annual Conference on Tissue Repair, Replacement and Regeneration (TR3).

CUPERTINO, Calif., Oct 15, 2001 /PRNewswire via COMTEX/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, October 31, 2001 at 4:30

CUPERTINO, Calif., Sept. 24 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Judy Magruder has been promoted to the position of Senior Vice President of Regulatory and Development and Tai Wah Chan, Ph.D. has been promoted to Vice President of Pharmaceutical Research and

CUPERTINO, Calif., Sept. 5 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the results of its Phase II clinical trial for its lead product Chronogesic(TM), a 3-month continuous infusion subcutaneous implant for the treatment of chronic pain.

CUPERTINO, Calif., Aug 24, 2001 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) press release regarding Chronogesic(TM) Phase II clinical trial data, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, September 5,

CUPERTINO, Calif., July 30 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2001. The company's net loss attributable to common stockholders for the three months ended June 30, 2001 was $7.0 million or 15 cents per share

CUPERTINO, Calif., Jul 19, 2001 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, July 30, 2001 at 4:30 p.m.

CUPERTINO, Calif., Jul 6, 2001 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that its Board of Directors adopted a Stockholder Rights Plan. The Rights Plan is designed to protect and maximize the value of stockholders' interest in DURECT Corporation, to enable all DURECT

CUPERTINO, Calif., June 29 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the preliminary results of its Phase II clinical trial for its lead product, a 3-month continuous infusion subcutaneous implant for the treatment of chronic pain.

CUPERTINO, Calif., Jun 25, 2001 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has filed a Special 510(k) pre-market notification with the FDA for its next generation ear delivery catheter. Like its predecessor IntraEAR(R) catheters, the Microdose Cath(TM) is intended for

CUPERTINO, Calif., June 25 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has filed a Special 510(k) pre-market notification with the FDA for its next generation ear delivery catheter. Like its predecessor IntraEAR(R) catheters, the Microdose Cath(TM) is intended for the

CUPERTINO, Calif., May 24 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX - news) today announced that it has completed construction of a commercial manufacturing facility that is expected to meet DURECT's production needs for Phase III clinical batches, FDA registration batches and commercial

CUPERTINO, Calif., May 11 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the company has completed the clinical portion of its Phase II clinical trial for the company's lead product, DUROS sufentanil. The last patient visit was completed and data analysis and report writing

CUPERTINO, Calif., April 30 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2001. The company's net loss attributable to common stockholders for the three months ended March 31, 2001 was $4.9 million or 11 cents per share,

CUPERTINO, Calif., April 30 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has acquired Southern BioSystems, Inc. ("SBS"), a privately held company located in Birmingham, Alabama. SBS develops, manufactures and sells biodegradable polymer and non-polymer drug delivery

CUPERTINO, Calif., April 24 /PRNewswire Interactive News Release/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, April 30th, 2001 at

CUPERTINO, Calif., April 3 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dennis M. Fisher, M.D. has been promoted to the position of Vice President for Medical Affairs. Dr. Fisher joined DURECT in June 2000 as Medical Director. Dr.

CUPERTINO, Calif., March 27 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has a long-term supply agreement with Mallinckrodt, a global manufacturer and marketer of specialty medical products. Mallinckrodt will supply DURECT's clinical and commercial requirements for

CUPERTINO, Calif., March 9 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the company has completed patient enrollment of its Phase II clinical trial for the company's lead product, DUROS sufentanil. Over 50 patients at 10 clinical centers were enrolled in the trial more

CUPERTINO, Calif., March 1 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Armand P. Neukermans Ph.D. to its Board of Directors. Dr. Neukermans is currently Chief Technical Officer of the Xros division at Nortel Networks. Dr.

CUPERTINO, Calif., March 1 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present a company overview and discuss the Phase II trial in progress for its lead product, DUROS sufentanil for the treatment of chronic pain, at the 1st Annual Salomon Smith Barney Specialty

CUPERTINO, Calif., Feb. 16 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2000 and reports strong progress in the company's business operations. The company reiterated its accelerated progress in the Phase II

CUPERTINO, Calif., Feb. 15 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2000. The Company's net loss attributable to common stockholders for the three months ended December 31, 2000 was $4.9 million or 11 cents

CUPERTINO, Calif., Feb. 7 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the company expects to complete enrollment of its 50 patient Phase II clinical trial for the company's lead product, DUROS sufentanil, ahead of the previously anticipated date for completion of

CUPERTINO, Calif., Jan. 24 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Evelyn R. Robledo has been promoted to Vice President of Quality Assurance and Compliance. Ms. Robledo joined DURECT in March 2000 and, utilizing her solid understanding of FDA regulations, developed

CUPERTINO, Calif., Jan. 22 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, February 15, 2001 at 4:30 p.m.

CUPERTINO, Calif., Dec. 12 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will present a company overview and discuss the Phase II trial in progress for its lead product, DUROS sufentanil for the treatment of chronic pain, at the 19th Annual Healthcare Conference to be

CUPERTINO, Calif., Dec. 11 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced enrollment of the patients into a Phase II clinical trial for the company's lead product, DUROS sufentanil, for the treatment of chronic pain. DUROS sufentanil uses the DUROS osmotic delivery system to

CUPERTINO, Calif., Nov. 13 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2000. DURECT's net loss attributable to common stockholders for its third quarter ended September 30, 2000 was $6.0 million dollars, or $0.62 cents

CUPERTINO, Ca., Nov. 7 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, November 13, 2000 at 4:30 p.m.

CUPERTINO, Calif., Nov. 2 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the underwriters of its recent initial public offering of common stock have exercised their over-allotment option in part and purchased an additional 700,000 shares at the initial public offering price

CUPERTINO, Calif., Oct. 23 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has commenced construction of a commercial manufacturing facility that is expected to meet DURECT's production needs for Phase III clinical trials currently planned for late 2001 and commercial

CUPERTINO, CA, September 28, 2000 – DURECT Corporation today announced the initial public offering of 7,000,000 shares of its Common Stock at a price to the public of $12 per share. Durect Corporation’s Common Stock will be listed on the NASDAQ National Market under the symbol “DRRX” and will begin

Cupertino, California - PRNewswire -- DURECT Corporation today announced that it has filed with the Securities Exchange Commission a registration statement relating to an initial public offering of its shares of common stock. All of the shares to be offered will be sold by the Company.

Pharmaceutical Firm Accelerates Activities in Ear Disorders Area Cupertino, California - PRNewswire -- DURECT Corporation, a pioneer in drug therapy treatments employing continuous drug delivery technology, today announced that it has acquired substantially all of the assets of IntraEAR, Inc.

San Diego, California - PRNewswire -- Genetronics Biomedical Ltd. (Amex: GEB; Toronto) today announced it has elected Felix Theeuwes, D.Sc., as a new member of its Board of Directors. Dr. Theeuwes is Chairman and Chief Scientific Officer at DURECT Corporation, which was established in 1998 to focus

PRNewswire -- DURECT Corporation, a pioneer in drug therapy treatments employing subcutaneous delivery technology, today announced the closing of a $20 million private placement of preferred convertible stock. The Series B placement led by Brookside Capital, a Bain Capital Fund, is DURECT's second